Tarka

Quick links to important sections

Tarka

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tarka

Quick Facts: Tarka

Property Description
Active Ingredients Trandolapril and Verapamil Hydrochloride
Form Extended-Release Tablet (Oral Dosage Form)
Pharmacological Class ACE Inhibitor and Calcium Channel Blocker (CCB)
General Purpose Antihypertensive Therapy (Sustained blood pressure control)
Origin Synthetic

Tarka: Definition and Pharmacological Class

Tarka is a prescription medication designed as a fixed-dose combination drug for managing high blood pressure. This medication is classified as an Angiotensin-Converting Enzyme (ACE) Inhibitor combined with a Calcium Channel Blocker (CCB), positioning it as an antihypertensive agent. The design utilizes the action of two separate antihypertensive classes in one pill, streamlining the treatment protocol. This combination strategy addresses pressure regulation through dual mechanisms—vascular relaxation and hormonal system modulation—simultaneously.


Composition and Formulation: Trandolapril and Verapamil

The medication's effectiveness is based on its two active ingredients: Trandolapril and Verapamil Hydrochloride. The drug is formulated as an extended-release tablet, ensuring both active components are released steadily over time. This specialized, controlled-release design is a key differentiating factor, setting it apart from immediate-release formulations and supporting consistent drug levels throughout the day for continuous cardiovascular function modulation. Trandolapril provides the ACE Inhibitor component, while Verapamil Hydrochloride provides the CCB effect.


What Is the General Purpose of This Combination Drug?

The general purpose of this fixed-dose combination drug is to achieve a sustained reduction in blood pressure. This results from the dual mechanism of effect: Trandolapril modulates the body’s Renin-Angiotensin-Aldosterone System (RAAS), while Verapamil primarily promotes peripheral vasodilation and eases the heart's workload. In clinical use, this combination is indicated for patients who require the sustained effects of both agents to manage their condition. In practice, the use of Tarka is typically reserved for adult patients who need robust, long-term control to support proper circulation.

Regulatory References

  1. Trandolapril and Verapamil: MedlinePlus Drug Information
  2. EMA Public Assessment Reports (EPARs)

What side effects are possible with Tarka?

The possible adverse reactions associated with Tarka are officially classified by regulatory bodies based on the frequency of their occurrence in clinical use.

Frequency-Classified Adverse Reactions

The most frequent adverse reaction documented in the label is constipation, which is classified as very common. Other effects categorized as common include headache, dizziness, cough, nausea, diarrhea, and fatigue. Less frequently reported reactions may include hypotension (low blood pressure), rash, pruritus, and bradycardia (slow heart rate).

System-Organ Classification

Adverse reactions are grouped according to the body system affected, with documented effects involving the Nervous System (e.g., headache, dizziness), Gastrointestinal System (e.g., constipation, nausea), Cardiovascular System (e.g., hypotension, bradycardia), and Respiratory System (e.g., cough).

Serious Adverse Reactions and Safety Constraints

The official safety profile designates certain reactions as serious and clinically significant, including angioedema (swelling of the face, throat, or tongue), severe hypotension, renal failure, and potentially severe hepatotoxicity (liver damage). The label also notes that hyperkalemia (high potassium levels) is a risk associated with the medication's ACE inhibitor component. These serious events underscore the importance of safety monitoring.

Time-related patterns indicate that effects such as hypotension may be more noticeable upon treatment initiation or following a dose adjustment. Safety constraints officially state that the drug is contraindicated in patients with a history of angioedema related to previous ACE inhibitor use, specific heart conduction disorders, and severe renal impairment.

Population-Specific Safety Notes

Specific safety considerations are documented for certain populations. The medicine is contraindicated during pregnancy due to the risk of fetal injury or death. Patients with impaired renal or hepatic function require careful attention due to the potential for altered drug effects and increased risks, such as hyperkalemia.

Overdose and Emergency Response

Overdose and when to seek help

A suspected overdose of Tarka is associated with severe effects primarily on the cardiovascular system, which may be life-threatening. The regulatory profile defines this risk based on the dual components of the medication.

Documented Overdose Manifestations

Overdose manifestations officially documented include profound hypotension (severely low blood pressure) and severe bradycardia (abnormally slow heart rate), alongside serious cardiac conduction abnormalities such as high-degree Atrioventricular (AV) block. Severe outcomes listed in regulatory information include cardiogenic shock, asystole (cessation of heart activity), and central nervous system effects such as seizures and altered mental status.

Emergency Actions Mandated

Emergency medical attention is mandated in the event of a suspected overdose. Immediate contact with emergency services (911) is required if the affected individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. The official guidance also advises contacting the Poison Control Helpline.

Supportive and Monitoring Requirements

Treatment is symptomatic and supportive, addressing the hemodynamic effects. The treatment protocol for the Verapamil component may involve parenteral administration of calcium solutions or beta-adrenergic stimulation. Due to the extended-release formulation, prolonged hospital monitoring and continuous observation are necessary to manage the risk of delayed or sustained toxicity.

Therapeutic Uses of Tarka

Tarka is commonly used to help with the management of high blood pressure (hypertension). Its therapeutic domain is applied in addressing symptoms related to systemic imbalance. The medication is relevant in conditions characterized by periods of heightened symptoms and is often used during phases when symptoms become more noticeable. This treatment is relevant in contexts marked by increased systemic burden associated with consistently elevated pressure.


Core Management and Supportive Relief

Tarka is generally used to help with the management of this chronic condition, which is a significant factor in symptoms that create noticeable physiological strain. It provides support that helps ease the overall symptom burden associated with the disease. The medication is generally relevant for conditions presenting with systemic or localized discomfort, addressing symptom clusters that may become intense or disruptive, and supporting patients during episodes of heightened discomfort.

“The therapy is relevant when supportive symptom management is appropriate and contributes to improved comfort during symptomatic periods.”


Quick Fact: Support for Systemic Imbalance


Tarka supports patients during episodes of heightened discomfort as it is applied in settings marked by temporary physiological imbalance. It assists with maintaining functional stability when symptoms become more noticeable. This medication may assist with maintaining functional stability.

Regulatory References

  1. Trandolapril and Verapamil: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Population Eligibility and Restrictions

Tarka is approved for use strictly in adult patients with essential hypertension, generally reserved for those whose blood pressure is already controlled on the individual components (Trandolapril and Verapamil). It is not indicated for the initial therapy of high blood pressure.

Absolute Contraindications

Use is contraindicated in several specific populations due to the risks associated with its components. Patients must not use Tarka if they have:

  • A history of angioedema related to any ACE inhibitor.
  • Severe renal impairment (creatinine clearance < 30 mL/min) or those on dialysis.
  • Severe left ventricular dysfunction, cardiogenic shock, or severe heart rhythm disorders (e.g., Second- or Third-degree AV Block without a pacemaker).
  • Liver cirrhosis with ascites.

Age and Life Stage Constraints

The medicine is strictly contraindicated for children and adolescents (< 18 years) as safety and efficacy have not been established. Use is contraindicated during the second and third trimesters of pregnancy and is not recommended while breastfeeding.

Condition-Based Limitations

Use is also not recommended for patients with severe hepatic impairment. Tarka is contraindicated when co-administered with certain medications, including Sacubitril/Valsartan, and Aliskiren in patients with diabetes or renal impairment.

What should I know about interactions with other medicines?

Tarka Interactions with other medicines and products

Official government documents specify several important medicine and substance interactions due to the combination of its two active ingredients, trandolapril and verapamil.

Interaction Type Interacting Medicines and Products
Do Not Combine (Contraindicated) Sacubitril-containing products (e.g., sacubitril/valsartan) require a 36-hour washout period before starting or after stopping this medication. Also, Intravenous beta-blockers and intravenous dantrolene.
Caution/Monitor Closely Other antihypertensive drugs, including diuretics, beta-blockers (oral), and other calcium channel blockers, may result in additive effects on blood pressure or heart rhythm. Agents that increase serum potassium, such as potassium supplements or certain diuretics (potassium-sparing), must be closely monitored.
CYP3A4/P-gp Effects Medicines that inhibit or induce the CYP3A4 enzyme system or P-glycoprotein (P-gp) transport system may alter the levels of the verapamil component or the co-administered drug. This includes agents like rifampin, carbamazepine, and statins (e.g., simvastatin).
Food and Supplements Grapefruit and grapefruit juice should be avoided. Potassium-containing salt substitutes or supplements are restricted.

These constraints are based on the risk of increased hypotension, heart-related adverse effects (e.g., slow heart rate, conduction problems), increased risk of hyperkalemia, and angioedema. Co-administration with aliskiren is restricted in patients with diabetes or certain kidney conditions. The official interaction profile requires specific restrictions to manage the combined pharmacodynamic and pharmacokinetic effects of its components.

Mechanism of Action

Tarka is a fixed-dose combination composed of two pharmacologically distinct agents: trandolapril and verapamil. The mechanism involves dual-pathway modulation of the cardiovascular system.

Trandolapril Component Trandolapril, a prodrug, is converted hepatically to its active metabolite, trandolaprilat. This metabolite acts as a competitive inhibitor of Angiotensin-Converting Enzyme (ACE), an enzyme crucial to the Renin-Angiotensin-Aldosterone System (RAAS). ACE inhibition prevents the conversion of angiotensin I to the potent vasoconstrictor, angiotensin II. This action reduces systemic vasoconstriction and lowers aldosterone secretion, resulting in decreased fluid reabsorption and a subsequent reduction in circulating volume.

Verapamil Component Verapamil is a non-dihydropyridine calcium channel blocker. Its mechanism involves the modulation of ionic calcium influx by blocking voltage-dependent L-type calcium channels on the cell membranes of both vascular smooth muscle and myocardial tissue. In vascular smooth muscle, this blockade reduces intracellular calcium concentration, resulting in vasodilation. In the myocardium and the cardiac conduction system, L-type channel inhibition reduces the force of contraction and slows atrioventricular (AV) nodal conduction velocity.

Dosage and Administration Information

How Tarka Is Used: Administration Guidelines

This section outlines the administration and dosing procedures for Tarka (Trandolapril/Verapamil HCl extended-release tablets), defining how the medicine is used in clinical practice.


Administration Scope

Instruction Type General Administration Guidelines
Route of Administration The drug is for oral administration only.
Dosing Schedule Initial dosing typically starts at 1 mg/240 mg or 2 mg/180 mg once daily. The maintenance dose may range up to a maximum recommended daily dose of 4 mg/240 mg.
Timing in Relation to Meals Tarka may be taken with or without food.
Preparation Requirements The extended-release tablet must be swallowed whole with liquid; it must not be crushed, chewed, or divided to preserve its controlled release properties.

Usage Patterns and Adjustments

  • Frequency: The standard regimen requires the medicine to be taken once daily (q.d.).
  • Titration Interval: Dosage adjustments, if necessary, should only be made at intervals of no less than 2 weeks to allow the full therapeutic effect to stabilize.
  • Population Adjustments: Guidelines specify that patients with renal or hepatic impairment may require a reduced initial dose of the Trandolapril component, indicating a need for careful regimen initiation in these groups.
  • Missed Dose: In the event of a missed dose, the patient should typically omit the dose and resume the normal scheduled time; a double dose should not be taken to compensate for the missed one.

Connection to the Overall Use Protocol

These instructions establish a standardized, long-term protocol for administration, emphasizing the importance of the once-daily schedule and the physical integrity of the extended-release tablet. The structured titration interval and specific dosage rules for impaired populations define the standardized approach to initiating and maintaining therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tarka

The clinical evaluation for Tarka (trandolapril/verapamil sustained-release) is derived from official health regulatory documents and peer-reviewed scientific literature. This research has examined how the combination is used to address high blood pressure and specific cardiovascular needs, monitoring outcomes related to physiological strain and functional imbalance.


Evidence for Use in Managing Essential High Blood Pressure

Studies exploring the use of Tarka in adults with essential high blood pressure primarily consist of Randomized Controlled Trials (RCTs). The goal of this research was to understand patterns related to the change in blood pressure measurements over time. Research examined how patient blood pressure levels were measured over a period of about 24 hours, and data show patterns related to sustained blood pressure measurements.

Findings indicate that the combination was studied as replacement therapy—that is, in patients whose blood pressure was controlled by the individual components. The standard short-term trials designed to measure blood pressure itself do not track long-term outcomes, such as major cardiovascular events like heart attack or stroke, over many years.


Research Focus on High Blood Pressure with Comorbidities

Studies have explored the use of the combination in adults who have high blood pressure along with other conditions, specifically Type 2 Diabetes or certain markers of primary renal disease. The research examined biomarkers in these groups, such as proteinuria and albuminuria, which are outcomes monitoring physiological strain on the kidneys. Findings describe patterns related to changes in these biomarkers, indicating the research monitored measurements beyond simple blood pressure control in these vulnerable populations.

However, the certainty remains low in some areas because the evidence quality varies across studies, and data often comes from larger strategic trials where the fixed-dose pill was part of a broader treatment plan. The specific long-term impact of the fixed-dose combination on these comorbid conditions is not fully established.


Evidence in Specific Patient Populations

The research has explored the combination’s use across different adult age groups, including specific studies focusing on older adults (ge 65 years). Data show patterns related to how blood pressure measurements evolved in these groups. However, data for certain groups remain insufficient. Specifically, there is no established safety and efficacy data for children or adolescents (under 18 years), as research has not been conducted in this population. Therefore, the results apply only to the adult populations studied.

Key Studies & References Antihypertensive and renoprotective effects of trandolapril/verapamil combination: a meta-analysis of randomized controlled trials - NCBI

Frequently Asked Questions (FAQ)

Common questions about Tarka (FAQ)


Q: How quickly does Tarka start to work after the first dose?

The Trandolapril component's key enzyme inhibition begins to peak within a few hours of the first dose, according to studies. However, official information notes that the full therapeutic effect is generally not assessed for stabilization until after approximately two weeks of consistent use.

Q: How long does the effect of Tarka last each day?

The official product information confirms that Tarka is an extended-release tablet. This formulation is designed to release active ingredients steadily to support blood pressure control over the entire 24-hour dosing period, consistent with a once-daily regimen.

Q: Can Tarka interact with common pain relievers like ibuprofen?

Official documentation advises caution regarding the combined use of this medication with nonsteroidal anti-inflammatory drugs (NSAIDs), a class that includes common pain relievers. This combination may affect kidney function or reduce blood pressure control, and caution and professional monitoring are described in the official guidance.

Q: Can Tarka be used by people with diabetes?

Clinical studies have included adult patients with Type 2 Diabetes. However, regulatory documents include a specific restriction: the drug is contraindicated when co-administered with Aliskiren in patients who have either diabetes or certain kidney conditions.

Q: Is Tarka only used for high blood pressure?

While the main approved indication is for managing essential high blood pressure, studies have also explored its patterns of use in patients with hypertension who also have coronary heart disease or specific markers of primary renal disease. These explorations are described in official documents.

Q: What happens if I miss a dose of Tarka?

Official administration instructions generally state that a missed dose should be omitted, and the patient should resume the normal scheduled time. It is specified that you should not take a double dose to make up for the missed one.

Q: Is it okay to drink alcohol while taking Tarka?

Official guidance cautions that consuming alcohol while taking this medicine may increase the risk of side effects like drowsiness and could lead to a greater reduction in blood pressure than usual. This may worsen feelings of dizziness or lightheadedness.

Q: Can Tarka interact with dietary supplements or herbal products?

General caution is advised due to the medication’s complex profile. Specifically, official guidance requires monitoring when used with certain substances that can increase serum potassium levels, such as potassium supplements or certain salt substitutes.

Q: Are there different strengths of Tarka available?

Yes, Tarka is supplied in multiple different extended-release tablet strengths according to official documentation. These strengths are fixed combinations of the two active ingredients, such as 1 mg/240 mg and 2 mg/180 mg.

Q: Why do doctors often prescribe a combination pill like Tarka instead of separate medications?

Regulatory reports indicate that this fixed-dose design is recognized for addressing blood pressure regulation through dual mechanisms simultaneously. This streamlined approach is clinically noted for its potential to support long-term patient adherence to the treatment protocol.

Q: Can Tarka lead to electrolyte imbalances?

Regulatory information notes a risk of hyperkalemia (high potassium) due to the ACE inhibitor component. Changes in other electrolytes, such as hyponatremia (low sodium), are also noted as observations from clinical laboratory testing.

Q: Does Tarka affect sleep?

Sleep-related issues are not listed among the frequently reported adverse effects in the safety profile. However, official documents do note other reactions affecting the nervous system, such as dizziness and drowsiness.

Q: Can Tarka interact with antacids?

Official drug interaction guidance advises caution. Certain antacids and other medicines taken by mouth could potentially interfere with the absorption of the verapamil component in the combination pill.

Q: Does Tarka affect cholesterol levels?

Tarka is not primarily intended to treat cholesterol. However, the verapamil component can interact with certain statins (cholesterol-lowering drugs), and official documents state that dose limits or monitoring may be necessary when these medicines are taken together.

Q: Is weight gain a possible side effect of Tarka?

Weight gain itself is not listed among the most common adverse reactions. However, important safety documents note that swelling (edema) and signs of heart failure can lead to weight increases, which are important concerns to monitor.

Q: Does Tarka make you more sensitive to the sun?

Official documentation does not explicitly list 'photosensitivity' or sun sensitivity as a recognized adverse effect. While general skin reactions like rash are noted, sun-related sensitivity is not a reported effect in the regulatory summaries.

Q: Can Tarka cause swelling in the ankles or feet?

Yes, swelling (or edema) is listed as a possible side effect in the official safety profile. Serious, rapid swelling of the face, tongue, or throat (angioedema) is also specifically noted as a clinically significant, serious risk associated with the medication.

Q: Does Tarka have a 'black box' warning, as sometimes seen for other drugs?

Yes, the official labeling for Tarka includes a Boxed Warning, which is the strongest type of warning required by the FDA. This warning concerns Fetal Toxicity, advising that drugs acting on the renin-angiotensin system can cause injury and death to a developing fetus, and the drug should be stopped as soon as pregnancy is detected.

Q: What are the signs that Tarka might not be working for me?

The primary patterns indicating a lack of response include a failure to achieve the desired reduction in blood pressure or the occurrence of persistently uncontrolled hypertension. Conversely, excessively low blood pressure (hypotension) may also indicate the need for a review.

Q: Is Tarka generally well-tolerated?

Data from clinical trials shows that the medication has been associated with a low percentage of patient discontinuation due to adverse effects. The most frequent reactions reported, such as constipation, headache, and dizziness, were typically mild to moderate.

Q: Does the time of day I take Tarka matter?

The official instructions emphasize that the drug should be taken once daily. While a specific time is not mandated, official guidance suggests that taking the medication at the same time each day helps maintain consistent blood levels.

Q: Do people typically need to change their diet while on Tarka?

Official regulatory documents describe specific dietary restrictions related to interactions. The use of potassium-containing salt substitutes or supplements is restricted, and consuming grapefruit or grapefruit juice should be avoided.

Q: What does the research say about Tarka's use in patients with both hypertension and heart disease?

Research has explored the combination’s patterns of use in patients with high blood pressure and pre-existing heart conditions. Studies have explored patterns related to changes in certain cardiovascular measurements, including observations on exercise duration time in patients with coronary heart disease.

Q: Are there any studies comparing Tarka's ingredients to other blood pressure drugs?

Comparative studies have been conducted. Findings from these studies describe patterns of use as an alternative to combinations containing certain diuretics or beta-blockers in long-term management for some patient groups.

Q: Is Tarka widely studied in different ethnic groups?

The official FDA label for the Trandolapril component notes that its effectiveness has been observed in all races studied. Furthermore, studies have explored the combination’s use in specific geographic areas, such as a phase IV study conducted in Russian hypertension patients.

Q: What were the main findings of the clinical trials for Tarka?

The primary findings reported in official documents showed that the combination significantly lowered blood pressure, providing an additive antihypertensive effect compared to either component alone. Studies also reported that the combination had a pronounced effect on blunting the early morning rise in blood pressure.

How should Tarka be stored and disposed of?

Storage Conditions

Tarka tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medicine must be protected from excess moisture and heat, and should remain in its tightly closed original container. To ensure safety, it is a mandatory requirement to store Tarka out of the sight and reach of children.


Disposal Instructions

Official regulations require the proper disposal of unused or expired Tarka. The medicine must not be thrown into household trash or flushed down the toilet or poured into a drain to prevent environmental contamination. Patients should consult a pharmacist or local waste disposal company for instructions on how to dispose of the product safely according to local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tarka found in:

A-Z Index: